MEDIASSIST · NSE
Medi Assist Healthcare Services Limited
₹324.85
+1.15% (+₹3.7)
Prev. close
₹321.15
Volume
1,05,999
Delivery %
62.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Medi Assist Healthcare Services Limited
Medi Assist Healthcare Services Limited, together with its subsidiaries, provides third-party administration services for health insurance claims in India and internationally. The company offers MAtrix, a claims administration platform; MAven, a fraud, waste, and abuse prevention platform; MAven IDP, an intelligent document processing platform; MAven Insights, an analytics and decision intelligence platform; MAven Global, a global benefits administration platform; and Network-as-a-Service platform, which provides access to a healthcare provider network. It also provides business support, health management, consultancy, contact center support, and other allied services related to the healthcare and health insurance sector. The company was incorporated in 2000 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Healthcare Plans
CEO
Mr. Satish V.N. Gidugu
Headquarters
Bengaluru
Employees
6,661
Website
mediassist.inExchange
View on NSE ↗Key stats
Market cap
₹2,426.69 Cr
P/E ratio (TTM)
25.6
Dividend yield
0.62%
EPS (TTM)
₹12.69
Beta (1Y · daily vs NIFTY 50)
1.43
Shares float
6.63 Cr
EPS · quarter ended Jun 2026
₹3.71
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹502.38 Cr | ₹634.73 Cr | ₹723.32 Cr | ₹904.77 Cr | |
| EBITDA | — | — | ₹133.30 Cr | ₹130.63 Cr | ₹177.87 Cr | ₹178.89 Cr |
| ₹26.00 Cr | ₹64.00 Cr | ₹74.06 Cr | ₹66.94 Cr | ₹90.88 Cr | ₹87.89 Cr | |
| Diluted EPS | — | — | ₹10.76 | ₹9.84 | ₹12.86 | ₹12.14 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹545.00 Cr | ₹602.00 Cr | ₹702.00 Cr | ₹842.00 Cr | ₹1,158.00 Cr | ₹1,372.00 Cr | |
| — | — | ₹30.68 Cr | ₹26.33 Cr | ₹203.69 Cr | ₹54.40 Cr | |
| Stockholders' equity | ₹290.04 Cr | ₹337.00 Cr | ₹376.00 Cr | ₹472.00 Cr | ₹541.00 Cr | ₹839.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated. Inventory shows ₹0 for 2024-03-31, 2025-03-31, 2026-03-31 — a real filed figure, not a gap: positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies). 2021-03-31, 2022-03-31, 2023-03-31 have no Inventory figure at all reaching this deck yet — not verified as zero, not verified as positive — so they are left blank rather than assumed to match the filed zero.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹139.00 Cr | ₹64.00 Cr | ₹81.00 Cr | ₹66.00 Cr | ₹138.00 Cr | ₹118.00 Cr | |
| Investing cash flow | — | — | ₹-10.49 Cr | ₹-54.86 Cr | ₹-218.24 Cr | ₹-159.63 Cr |
| ₹-10.00 Cr | ₹-30.00 Cr | ₹-32.00 Cr | ₹-15.00 Cr | ₹112.00 Cr | ₹12.00 Cr | |
| Capital expenditure | ₹-13.00 Cr | ₹-12.00 Cr | ₹-28.00 Cr | ₹-18.00 Cr | ₹-46.00 Cr | ₹-56.00 Cr |
| End cash position | — | — | ₹53.94 Cr | ₹50.93 Cr | ₹83.01 Cr | ₹54.63 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jan 24 | Mar 24 | Jun 24 | Sep 24 | Dec 24–Mar 25(2Q) | Jun 25 | Sep 25 | Oct 25–Nov 25(2Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.67% | 38.91% | 38.85% | 20.60% | 20.56% | 20.55% | 4.87% | 4.63% | 4.62% | 4.61% |
| Public | 60.33% | 61.09% | 61.15% | 79.40% | 79.44% | 79.45% | 95.13% | 95.37% | 95.38% | 95.39% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Medi Assist Healthcare Services Limited | ₹2,399.05 Cr | ₹324.85 | 25.3 | 2.86 | 10.5% | 0.06 | +25.1% | -39.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Medi Assist Healthcare Services Limited (NSE:MEDIASSIST) Looks Interesting, And It's About To Pay A Dividend
simplywall.st · 12 days ago